AbstractBackground: Hypofractionated post-mastectomy radiotherapy (PMRT) offers a shorter treatment regimen for breast cancer patients, potentially improving patient compliance and resource efficiency. While studies support its safety in breast-conserving settings, its application in post-mastectomy scenarios requires further assessment.
Materials and Methods: This prospective study involved 25 breast cancer patients who underwent modified radical mastectomy and received hypofractionated PMRT. Patients were evaluated for acute toxicities weekly over six weeks. Treatment dosimetry followed established guidelines, with attention to clinical target volume (CTV) and organs-at-risk (OAR) dose limits.
Results: Most patients tolerated the treatment well, with no Grade IV toxicities. Acute side effects included dermatitis (56% Grade I, 16% Grade II) and mild fatigue. Only one patient developed Grade III dermatitis. Analysis revealed that higher BMI correlated with increased toxicity, though within tolerable limits. No significant dose violations occurred, and treatment completion rates were high.
Conclusion: Hypofractionated PMRT is a feasible, well-tolerated approach for post-mastectomy breast cancer patients, achieving acceptable toxicity levels and supporting future research into its standardization. BMI-specific dose adaptations may enhance treatment tolerance.
